Src inhibitors in early breast cancer: A methodology, feasibility and variability study

Breast Cancer Research and Treatment

Volumn 114, Issue 2, 2009, Pages 211-221

  Jones, R J ^a   Young, O ^b   Renshaw, L ^b   Jacobs, V ^c   Fennell, M ^c   Marshall, A ^c   Green, T P ^c   Elvin, P ^c   Womack, C ^c   Clack, G ^c   Dixon, J M ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

AZD0530; Early breast cancer; Focal adhesion kinase; Immunohistochemistry; Paxillin; Phosphorylation; Src kinase

Indexed keywords

FOCAL ADHESION KINASE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PAXILLIN; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EARLY CANCER; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; TUMOR BIOPSY; TUMOR XENOGRAFT;

ANIMALS; BENZODIOXOLES; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; PAXILLIN; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RATS; RATS, NUDE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59449087435     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9997-1     Document Type: Article

References (19)

1. MC Frame 2004 Newest findings on the oldest oncogene; how activated src does it J Cell Sci 117 989 998
2. RB Irby TJ Yeatman 2000 Role of Src expression and activation in human cancer Oncogene 19 5636 5642
3. AE Ottenhoff-Kalff G Rijksen EA van Beurden 1992 Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product Cancer Res 52 4773 4778
4. BS Verbeek TM Vroom SS Adriaansen-Slot 1996 c-Src protein expression is increased in human breast cancer An immunohistochemical and biochemical analysis J Pathol 180 383 388
5. D Reissig J Clement J Sanger 2001 Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue J Cancer Res Clin Oncol 127 226 230
6. Y Ito H Kawakatsu T Takeda 2002 Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma Breast Cancer Res Treat 76 261 267
7. N Rucci I Recchia A Angelucci 2006 Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy J Pharmacol Exp Ther 318 161 172
8. S Hiscox L Morgan NJ Jordan 2007 Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen resistant breast cancer cells Clin Exp Metastasis 24 157 167
9. S Hiscox L Morgan TP Green 2006 Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells Breast Cancer Res Treat 97 263 274
10. RS Finn J Dering C Ginther 2007 Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 105 319 326
11. S Hiscox L Morgan T Green 2006 Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer Endocr Relat Cancer 13 Suppl 1 S53 S59
12. Green T, Hennequin LF, Ple PA et al (2005) Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530. AACR Annual Meeting SSY01 Drugs on the Horizon Symposium
13. GW McLean VJ Fincham MC Frame 2000 v-Src induces tyrosine phosphorylation of focal adhesion kinase independently of tyrosine 397 and formation of a complex with Src J Biol Chem 275 23333 23339
14. A Rodina K Schramm E Musatkina 1999 Phosphorylation of p125FAK and paxillin focal adhesion proteins in src-transformed cells with different metastatic capacity FEBS Lett 455 145 148
15. RJ Jones T Boyce M Fennell 2008 The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers Cancer Chemother Pharmacol 61 23 32
16. H Kawakatsu T Sakai Y Takagaki 1996 A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase J Biol Chem 271 5680 5685
17. S Marchetti JH Schellens 2007 The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials Br J Cancer 97 577 581
18. B Booth R Glassman P Ma 2003 Oncology's trials Nat Rev Drug Discov 2 609 610
19. MC Frame 2002 Src in cancer: deregulation and consequences for cell behaviour Biochim Biophys Acta 1602 114 130